Celgene and BeiGene join for cancer drug | July 10, 2017 Issue - Vol. 95 Issue 28 | Chemical & Engineering News
Volume 95 Issue 28 | p. 15 | Concentrates
Issue Date: July 10, 2017

Celgene and BeiGene join for cancer drug

Department: Business
Keywords: biologics, China, PD-1 inhibitors

Celgene and BeiGene will jointly develop BeiGene’s investigational anti-programmed cell death protein 1 inhibitor, BGB-A317, in the U.S., Europe, Japan, and the rest of the world outside Asia, where BeiGene will retain rights. BGB-A317 is an antibody that treats solid tumors. Celgene will pay BeiGene a $263 million license fee and acquire a 5.9% stake in the Chinese firm. BeiGene will acquire Celgene’s operations in China and gain a license to commercialize Celgene’s approved therapies in China.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment